← Back to patent-cliff list
Domatinostat/Sirolimus
Tier C — Watch / tradeDomatinostat/Sirolimus
Vuja De Sciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HDAC2, HDAC1, HDAC3, mTORC1, mTORC2
Indications (approved)：Osteosarcoma
Regional status
US
Phase I
2025-09-01
EU
Phase II
2026-07-22
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Domatinostat/Sirolimus?
Approved indications include: Osteosarcoma.
When does the Domatinostat/Sirolimus patent expire?
No public expiry year is available for Domatinostat/Sirolimus yet; this page updates once verified.
How do I get a quote for Domatinostat/Sirolimus intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29